• SELLAS Life Sciences Group reported that its REGAL trial for lead cancer vaccine candidate galinpepimut S has reached 78 events, just two short of triggering final analysis, while Phase 2 enrollment for SLS009 in newly diagnosed AML patients continues with topline data expected in the fourth quarter of 2026.
• The pairing of an imminent REGAL data readout and upcoming SLS009 topline results places SELLAS Life Sciences Group’s pipeline execution and trial design under sharp focus for investors assessing its clinical risk profile.
• The focus now turns to how SELLAS Life Sciences Group’s investment narrative could shift as the REGAL trial approaches its long awaited final analysis.

Scan beyond SELLAS Life Sciences Group to see how other…